On Sept. 24, 2014Heart Hospital of Austin became the first facility in Texas to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF). The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure.

Amgen today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas.

Cardiac Dimensions, Inc. today announced that new long-term outcomes data from the TITAN II clinical trial of its enhanced CARILLON Mitral Contour System showed significant and sustained improvements in mitral regurgitation, functional improvement, quality of life and reverse cardiac remodeling. The long-term safety and efficacy data, which was consistent with previous trials of the system, was presented Sept. 13 at the 26th annual Transcatheter Cardiovascular Therapeutics Conference (TCT) in Washington, DC by TITAN II investigator Professor Dr. Michael Haude of Lukaskrankenhaus in Neuss, Germany.

Cardioxyl Pharmaceuticals, Inc. announced today that its experimental heart failure compound has been shown to be effective in animal models following oral (capsule) dosing. The preclinical results demonstrate an alternative to intravenous infusions that could pave the way for convenient outpatient therapy with HNO prodrugs. The data were presented yesterday at the Heart Failure Society of America’s (HFSA) 18th Annual Scientific Meeting in Las Vegas.

Experts discussed the benefits of Home Monitoring technology from the perspective of patients, hospitals and payers for the first time at a press conference held by BIOTRONIK at the European Society of Cardiology's annual congress, ESC Congress 2014.

Framingham, Mass., August 4, 2014 – HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the appointment of Katrin Leadley, M.D., as Chief Medical Officer of HeartWare, effective September 1, 2014. 

Regenerative medicine experts at the Cedars-Sinai Heart Institute have opened a new clinic to evaluate heart and vascular disease patients for participation in stem cell medical studies.

Muscle physiologist Edward Debold at the University of Massachusetts Amherst's School of Public Health and Health Sciences recently received a three-year, $198,000 grant from the American Heart Association to support studies to uncover the molecular mechanisms of skeletal muscle fatigue.